Loading…

Merck & Co.MRKCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Major pharma known for oncology drug Keytruda, vaccines (Gardasil, pneumococcal) and animal health.

Momentum strong 63
Mkt cap
$340B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$1.38B
20-day average traded
Fwd P/E
16.4×
forward earnings
ROIC−WACC
+4.6 pp
WACC 6.4%
Hurdle
-1 pp
Req g minus delivered
Official | Implied
A+ / AA-
agencies · bond market
Next earnings
76 days
2 Feb 2027
Close · USD$137.78
1D-3.9%
1W-6.4%
1M-7.1%
3M-7.5%
6M+22.8%
YTD+32.8%
1Y+51.8%
ATR %3.1%
Beta0.26
52w lowhigh12.2% off high

What Merck & does

Major pharma known for oncology drug Keytruda, vaccines (Gardasil, pneumococcal) and animal health.

Sells patented medicines and vaccines through payers, hospitals and government immunisation programmes, with Keytruda for cancer the biggest single product; animal health is a separate business sold to veterinarians. Keytruda loses patent protection around 2028, so it is working to replace it with new products and an under-the-skin version.

Products and services

  • Keytruda (oncology)
  • Gardasil (HPV vaccine)
  • Animal health
  • Cardiovascular/diabetes

Customers

  • Oncologists/health systems
  • Governments/immunization programs
  • Veterinarians

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded biopharma
  • Oncology, vaccines, animal health

What could go right

  • Keytruda life-cycle extension via new indications
  • Animal health growth

What could go wrong

  • Keytruda patent expiry (~2028)
  • Gardasil demand softness in China

Moat: wide (IP / patents, scale, brand). Keytruda's broad label across cancers and Gardasil's franchise generate durable, hard-to-replace demand.

Headquarters: Rahway, New Jersey, United States · Founded: 1891 · Employees: 75,000

Named competitors

Merck & at a glance

Size Merck & (MRK) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $340B, the 29th largest of 3,085 United States companies the cockpit tracks. Shares closed at $137.78 on 18 Nov 2026.

Performance Over six months the shares gained 22.8%, against +13.0% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 14 in its peer set.

Growth Revenue grew 5.2% over the last twelve months (peer median +5.7%); the operating margin is 18.4% (peer median 30.5%).

Valuation It trades at 16.4× forward earnings against a peer median of 17.5× (7th cheapest of 14).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.6 points above its cost of capital (6.4% WACC).

Credit Merck & has 45 bonds outstanding ($46.7B), rated A+ by the agencies and trading like AA- at a weighted spread of 67 bp.

Short interest Short interest is 1.1% of the free float (30 Oct 2026).

Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026MRK 120Peer median 112
Six months, rebased to 100: Merck & against the median of its 13 peers (local-currency closes).

Merck & financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$67.2B$64.9B$64.0B$59.9B$58.5B
Revenue growth—+1%+7%+2%—
Gross profit$48.0B$46.7B$47.2B$43.9B$41.3B
EBITDA$19.6B$29.3B$25.1B$6.85B$23.4B
Net income$2.45B$18.3B$17.1B$365M$14.5B
Free cash flow$14.7B$12.4B$18.1B$9.14B$14.7B
Capital expenditure$3.96B$4.11B$3.37B$3.86B$4.39B
Total debt$53.8B$50.5B$38.3B$36.3B$32.0B

Quarterly statements and history in the cockpit →

Merck & competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%RONOVNAZNABBVNOVO-BJNJPFEBMYSANGSKREGNLLYMRK6-month return →1-month return →
Up and to the right = strong over both horizons. Merck & is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×20×30×RONOVNAZNABBVNOVO-BJNJPFEVRTXBMYSANGSKREGNLLYMRKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Merck & is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%-10%0%10%20%RONOVNAZNABBVNOVO-BJNJPFEVRTXBMYSANGSKREGNLLYMRKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Merck & is the large dot.

Merck & competitors and peer comparison

Head to head with its named competitors (MRK vs BMY vs RO.SW vs PFE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Merck & MRK$340B+23%+5%18%16.4×8.3%
Bristol Myers Squibb BMY$122B+3%+4%33%9.2×-13.1%
Roche RO.SW$381B+21%-1%31%19.9×1.7%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%

How Merck & compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Merck & against its 13 peers (data as of 18 Nov 2026)
MeasureMRKPeer medianRank in peer set
1-month return-7.1%+3.9%lowest of 14
6-month return+22.8%+13.0%5th highest of 14
Distance from 52-week high-12.2%-6.0%5th lowest of 14
Revenue growth (TTM)+5.2%+5.7%7th lowest of 14
Operating margin18.4%30.5%lowest of 14
Forward P/E16.4×17.5×7th cheapest of 14
Growth the price implies (Req g, 7 yrs)8.3%-0.1%2nd most demanding of 14
Growth delivered (Del g)+9.3%+6.0%6th highest of 14
Hurdle (Req g minus delivered)-1.1 pp-8.0 pp5th most demanding of 14
ROIC minus cost of capital+4.6 pp+11.8 pp4th lowest of 14
EV / EBITDA19.6×15.5×4th most expensive of 14
Net debt / EBITDA2.2×1.0×most indebted of 14
Bond spread67 bp65 bp7th tightest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Merck & MRKUnited States$340B+23%+5%18%16.4×8.3%+9.3%
Roche RO.SWSwitzerland$381B+21%-1%31%19.9×1.7%+1.1%
Novartis NOVN.SWSwitzerland$285B+11%-4%30%17.5×1.6%-0.2%
AstraZeneca AZN.LUnited Kingdom$278B-2%+5%23%17.6×14.4%+15.7%
AbbVie ABBVUnited States$506B+35%+11%36%18.1×-0.1%+6.0%
Novo Nordisk A/S NOVO-B.CODenmark$177B-6%+6%48%11.8×-0.5%+19.5%
Johnson & Johnson JNJUnited States$656B+20%+8%26%24.2×3.7%+2.7%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
Lilly (Eli) LLYUnited States$1.30T+36%+46%51%29.5×6.5%+21.6%

Merck & bonds and credit

Merck & has 45 bonds outstanding with $46.7B face value. The agencies rate it A+; its bonds trade like AA-. Weighted yield 5.60%, a spread of 67 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Merck &'s main competitors?
Named competitors: Bristol Myers Squibb (BMY), Roche (RO.SW), Pfizer (PFE), AstraZeneca (AZN.L). The cockpit's measured peer set (industry) also includes Roche (RO.SW), Novartis (NOVN.SW), AstraZeneca (AZN.L), AbbVie (ABBV), Novo Nordisk A/S (NOVO-B.CO), Johnson & Johnson (JNJ).
Is Merck & expensive compared with its peers?
On forward p/e it trades at 16.4× against a peer median of 17.5×, 7th cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Merck & stock performed?
Over six months to 18 Nov 2026 the shares returned +22.8% against +13.0% for the median peer; over one year +51.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.